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Background: The knowledge of Epidermal growth factor receptor (EGFR) expression in metastases of NSCLC was
limited. In receptor-mediated targeted nuclide radiotherapy, tumor cells are killed with delivered radiation and
therapeutic efficiency is mainly dependent on the receptor expression. Thus, the level and stability of receptor
expression in both primary tumors and corresponding metastases is crucial in the assessment of a receptor as
target. The goal of this study was to evaluate whether EGFR is suitable as target for clinical therapy.
Methods: Expression of EGFR was investigated immunohistochemically in paired samples of lymph node
metastases and corresponding NSCLC primary lesions (n = 51). EGFR expression was scored as 0, 1+, 2+ or 3+.
Results: Positive (1+, 2+ or 3+) EGFR immunostaining was evident in 36 of 47 (76.6%) analysed NSCLC primary
tumors, and in 78.7% of the corresponding lymph node metastases. When EGFR expression is classified as positive
or negative, discordance between the primary tumors and the corresponding metastases was observed in 5 cases
(10.6%). EGFR overexpression (2+ or 3+) was found in 53.2% (25/47) of the NSCLC primary tumors and 59.6% of
the corresponding metastases. Nine out of the 47 paired samples (19.2%) were discordant: Only three patients who
had EGFR overexpression in the primary tumors showed EGFR downregulation (0 or 1+) in lymph node metastases,
while six patients changed the other way around.
Conclusions: The EGFR expression in the primary tumor and the corresponding metastasis is discordant in about
10% of the patients. When overexpression is considered, the discordance is observed in about 20% of the cases.
However, concerning EGFR overexpression in the primary tumors, similar expression in the metastases could be
predicted with a reasonably high probability, which is encouraging for testing of EGFR targeted nuclide
radiotherapy.
Background
Lung cancer is the leading cause of cancer-related mor-
tality in China and in western countries, approximately
thirty percent of all cancer-related deaths are because of
lung cancer [1]. Non-small cell lung cancer (NSCLC)
accounts for 75-80% of all lung cancers [2]. Of all
patients with newly diagnosed NSCLC, 65-75% have
advanced, unresectable disease [2,3]. Up to half of
patients with NSCLC develop metastases at the time of
the initial diagnosis [4], and more patients eventually
experience metastases in the course of their disease. For
stage III/IV NSCLC, platinum-based combined che-
motherapy has been considered as the standard thera-
peutic modality [5-7]. However, such treatment remains
suboptimal with median survival time ranging from 7.4
to 10.3 months [8,9], and the 1-year survival is just
around 30%. Although small molecular tyrosine kinase
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any medium, provided the original work is properly cited.inhibitors (TKIs) against Epidermal growth factor recep-
tor (EGFR), such as gefitinib and erlotinib, have been
developed with the hope of improving response to tradi-
tional cytotoxic agents, only a limited percentage (12%-
27%) of patients seem to benefit from such agents
[10-13]. The addition of Cetuximab, an anti-EGFR IgG1
monoclonal antibody, to platinum-based chemotherapy
has been regarded as a new standard first-line treatment
option for patients with EGFR-expressing advanced
NSCLC. However, adding cetuximab to a platinum-
based doublet achieved only marginal benefits with an
overall survival advantage of 1.2 months (11.3 months
vs 10.1 months) compared to chemotherapy alone [14].
Additional therapeutical approaches are clearly needed
to improve the survival and the quality of life for
patients with recurrent and disseminated NSCLC.
Receptor-mediated tumor targeting nuclide radiother-
apy could be another option. In this therapeutic modal-
ity, tumor cells are killed with delivered radiation and
therapeutic efficiency is mainly dependent on the recep-
tor expression and not whether the receptor function
can be blocked or not [15]. Thus, receptor overexpres-
sion, together with a similar expression in both the pri-
mary tumors and the disseminated lesions, is considered
necessary for the success of targeted nuclide
radiotherapy.
EGFR is overexpressed in up to 80% of NSCLC
[16-18]. However, it is still uncertain whether the EGFR
protein expression determined in the primary tumors
exactly reflects the EGFR status of the metastatic tumors
in NSCLC patients. In the present study, the EGFR
expression was investigated immunohistochemically in a
series of 51 primary NSCLC samples and corresponding
lymph node metastases. The goal was to evaluate
whether the receptor is suitable as target for clinical
therapy, including radionuclide based therapy.
Methods
Patients and Samples
Patients with NSCLC who were treated with curative
resection for excision of primary tumor and correspond-
ing lymph nodes metastases, between 2006 and 2007,
were enrolled in the present study. Tumor samples from
all patients were obtained at the time of operation
through the Thoracic Surgery (Oncology) Department
and the Pathology Department, Ningbo Second Hospital,
under approval of the Institutional Review Board in
accordance with the Declaration of Helsinki. Paraffin sec-
tions from both the primary tumors and the correspond-
ing lymph node metastases were required for inclusion.
Tissue samples were not taken from distant metastases
so these were not available for analysis. Patients who had
received preoperative thoracic radiotherapy or preopera-
tive systemic chemotherapy were excluded. Patients who
had received anti-EGFR therapy were also excluded.
Totally, 51 patients were finally included in the study.
Clinical information was obtained from the hospital
records and included patient age, gender, disease stage,
and histological pattern. Lung cancer histology was
defined according to the World Health Organization
pathology classification [19]. Clinicalpathologic staging
was determined according to the International Union
Against Cancer tumor-node-metastasis classification of
malignant tumors [20]. The patient and tumor character-
istics of the analyzed cases are shown in Table 1.
EGFR-staining
The tissues were fixed in 4% buffered formalin, processed
and embedded in paraffin. Sections, 4-μm thick, were
then cut and deparaffinized in xylene and hydrated
through graded concentrations of ethanol to distilled
water. EGFR was assessed by immunohistochemistry as
previously described [21]. Briefly, after deparaffinization
of the sections, endogenous peroxidase was blocked in
0.3% H2O2 in PBS for 20 min. For antigen retrieval, the
sections were submitted to high temperature and pres-
sure with Tris-EDTA buffer (pH 9) for 5 min. The slides
were preincubated in PBS for 10 min. The primary
mouse monoclonal antibody directed against EGF recep-
tor (clone 31G7, Zymed labs, South San Francisco, CA,
USA) receptor was diluted 1:100, and incubated over-
night at 4°C. The secondary biotinylated antibodies (goat
anti-mouse from Dako, Glostrup, Denmark) and the per-
oxidase-labelled streptavidin-biotin complex (Dako) were
diluted 1:200 and incubated for 30 min at room tempera-
ture. All slides were developed in 0.05% diamino benzi-
dine (Sigma, St Louis, MO, USA) for 5 min and
counterstained in Harris haematoxylin (Sigma). Finally,
the slides were dehydrated through graded alcohol to
xylene and mounted in organic mounting medium.
EGFR-scores
EGFR stainings were mainly in the cell membranes and
the expression pattern of EGFR was quite similar to that
of HER2. Thus EGFR expression was therefore evaluated
using the HercepTest scoring criterion as reported in
previous studies [21-23]. Sections were considered as
positive when at least 10% of the tumor cells to be
stained. Cytoplasmic staining without associated mem-
brane staining was considered non-specific and was
reported as negative. The score was based on a scale
where 0 corresponded to tumor cells that were comple-
tely negative, 1+ corresponded to faint perceptible stain-
ing of the tumor cell membranes, 2+ corresponded to
moderate staining of the entire tumor cell membranes
and 3+ was strong circumferential staining of the entire
tumor cell membranes creating a fishnet pattern. As
positive controls we used in house positive control tis-
sue sections. As negative controls we used normal tis-
sues, which are expected not to express EGFR such as
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cells. In the metastases sections we used lymphocytes
and the surrounding capsule of the lymph nodes as
negative internal controls.
Excluded cases
In 3 cases, no tumor cells could be found in the sections
of lymph nodes. In another case, there were no tumor
cells in the sections supposed to be primary lung cancer.
Thus, we started from 51 patient cases and ended up
with 47 cases with high quality material of both primary
tumors and the corresponding metastases.
Results
EGFR expression of primary tumors and metastases
The EGFR-scores for the analyzed 47 primary NSCLC
and the corresponding 47 lymph node metastases are
shown in Table 2. In 36 of 47 (76.6%) analysed primary
tumors, immunostaining for EGFR was evident. Among
these, 11 (23.4%) had EGFR expression scored as 1+, 10
(21.3%) had EGFR expression scored as 2+, and 15
(31.9%) had EGFR expression scored as 3+. Accordingly,
negative EGFR staining was seen in 11 cases (23.4%) of
the analysed primary tumors. Positive EGFR expression
(1+, 2+ or 3+) was found in 78.7% (37/47) of the corre-
sponding lymph node metastases, the cases with EGFR
expression scored as 0, 1+, 2+ or 3+ were 10 (21.3%), 9
(19.1%), 18 (38.3%), and 10 (21.3%) respectively.
EGFR overexpression (2+ or 3+) was found in 53.2%
(25/47) of the NSCLC primary tumors and 59.6% (28/
47) of the corresponding lymph node metastases. Exam-
ple of staining pattern for a primary tumor and the cor-
responding metastasis (which both were scored as 3+) is
shown in Fig. 1A and 1B.
Comparison of the EGFR status between primary tumors
and metastases
When EGFR expression is classified as positive (1+, 2+
or 3+) or negative, a discordance was observed in 5
cases (10.6%): in 2 cases, EGFR was expressed in the pri-
mary tumor but not in the metastasis, while three sam-
ples showed EGFR expression in the metastasis but not
in the primary tumor. There was a good agreement
between the primary tumors and the corresponding
lymph node metastases in the majority of cases. EGFR
expression retains or gains in the metastases in more
than 95.7% (45/47) of the cases.
Regarding EGFR overexpression, nine out of the 47
paired samples (19.2%) were discordant for EGFR status
between the primary site and the metastases: only three
patients who had 2+ or 3+ in the primary tumors and
changed to 0 or 1+ in lymph node metastases, and
another six patients who had 0 or 1+ in the primary
tumors and changed to 2+ or 3+ in lymph node metas-
tases. The major results from the EGFR-score analyses
are summarized in Table 3.
Table 1 Tumour and patient characteristics (n = 51)
Characteristics Patients, n (%)







Squamous cell carcinomas 18 (35.3)
Adenocarcinomas 27 (52.9)
Bronchioloalveolar carcinoma 2 (3.9)
Adenosquamous carcinoma 4 (7.8)

















Table 2 EGFR-scores for the analyzed primary Non-small
cell Lung cancer and the corresponding lymph node
metastases (n = 47).
Primary tumor EGFR-scores Lymph node metastases EGFR-scores
01 +2 +3 +
0 8 210
1 + 1 541
2 + 0 190
3 + 1 149
The scoring was based on a scale where 0 corresponded to completely
negative staining, 1+ corresponded to faint perceptible staining of the tumor
cell membranes, 2+ corresponded to moderate staining of the entire tumor
cell membranes and 3+ was strong circumferential staining of the entire
tumor cell membranes creating a fishnet pattern
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Page 3 of 7Figure 1 Comparisons of immunohistochemical EGFR staining of primary non-small cell lung cancer (A) and corresponding
metastases (B). Both A and B (from the same patient) were scored 3+. The micrographs were taken with objective × 40.
Table 3 Major results from the EGFR-scores analyses of non-small cell lung cancer (n = 47).
EGFR-scores characteristics Cases %
Primary tumors with 2+ or 3+ 25 (53.2)
Lymph node metastases with 2+ or 3+ 28 (59.6)
Unchanged EGFR-scores in lymph node metastases vs. the primary tumor 31 (66.0)
Changed EGFR-scores in lymph node metastases vs. the primary tumor 16 (34.0)
Patients who had 0 or 1+ in primary tumors and changed to 2+ or 3+ in lymph node metastases 6 (12.8)
Patients who had 2+ or 3+ in primary tumors and changed to 0 or 1+ in lymph node metastases 3 (6.4)
Patients who had 0 in primary tumors and changed to 1+, 2+ or 3+ in lymph node metastases 3 (6.4)
Patients who had 1+, 2+ or 3+ in primary tumors and changed to 0 in lymph node metastases 2 (4.2)
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The knowledge of EGFR expression in metastases of
NSCLC was limited. It is still unclear whether the
metastases lose, gain or retain the receptor status rela-
tive to the primary tumors. For a receptor to be of inter-
est for targeting, a similar expression in both the
primary tumors and the disseminated lesions are
required. Investigation into the receptor status between
metastases and the primary tumors will provide valuable
information on whether the receptor is suitable as a tar-
get for diagnostic and/or therapeutic procedures. In the
present study, the expression of EGFR was investigated
immunohistochemically in paired samples from a series
of primary NSCLC lesions and corresponding lymph
node metastases.
EGFR expression (1+/2+/3+) was found in 76.6% of
the primary lesions and 78.7% of the lymph node metas-
tases. EGFR expression in NSCLC cancer has been
reported to be common (ranges from 40-80%) [16-18].
Our result is consistent with the former findings of high
EGFR expression in NSCLC [24,25]. Moreover, the fre-
quency of EGFR expression in lymph node metastases
was approximately as high as in the primary lesions of
NSCLC.
It is known that EGFR is commonly expressed in nor-
mal cells. When EGFR targeted radionuclide therapy is
delivered, possible side effects to normal tissues should
be taken into consideration. It might be possible to
minimize the toxicity and improve therapeutic efficiency
if a tumor and its metastases have a strong EGFR
expression to ensure higher tumor uptake than in most
normal tissues. So, EGFR overexpression (2+ or 3+) was
also analysed in the present study. EGFR overexpression
was found in 53.2% of the NSCLC primary tumors and
59.6% of the corresponding lymph node metastases.
To our knowledge, the question of EGFR protein
expression in metastases versus primary NSCLC, has
not been well addressed. Although totally 16 changes
were observed in the present study, switch from positive
EGFR expression in the primary tumor to negative in
the metastatic site was observed only in 2 cases (4.2%,
2/47) and negative to positive EGFR conversions occur
less than 6.5% of the cases (3/47). When overexpression
is considered, a discordance was observed in 19.2% of
the cases: only 3 patients with EGFR overexpression in
the primary tumor had lower EGFR scores in the corre-
sponding lymph node metastases. Moreover, in another
6 patients, EGFR overexpression was gained in lymph
node metastases while the primary tumors had low
scores. Although the currentr e p o r ti sl i m i t e db yt h e
small sample size, our observations suggest that positive
EGFR expression is relatively well-preserved during the
metastatic progression from primary NSCLC to lymph
node metastases. Therefore, concerning positivity, the
EGFR expression determined in the primary tumor is
predictive for the metastases. Recent studies on laryn-
geal, esophageal, and uterine cervical carcinoma also
found that the EGFR status of the primary tumor was
retained in the metastases [21-23].
There are few reports in the literature concerning
the stability of EGFR protein expression between
paired samples of NSCLC primary tumors and the cor-
responding metastases. In the studies by Italiano et al
[26] and Gomez-Roca et al [27], analyzed by immuno-
histochemistry, 33% of the cases with NSCLC showed
discordance in EGFR status between primary tumor
and metastases, suggesting that EGFR expression
might not be stable during metastasis progression.
However, according to the recent report by Badalian et
al, the expression status of EGFR protein was reported
to be highly similar in the bone metastasis compared
to that in primary NSCLC, without positive to negative
or negative to positive EGFR conversions occur in
their small cohort of NSCLC [28]. Individual compari-
son of corresponding primary and metastatic tissues
indicated that downregulation of EGFR was a rare
event (2/11 cases) while upregulation was observed
more frequently (4/11 cases), however, the expression
level was maintained in about half of the analyzed
cases. This observation suggests that EGFR expression
status is relatively well-preserved during metastatic
progression of NSCLC to the bone. In another study,
M i l a se ta l[ 1 8 ]r e p o r t e do na n a l y s i so fE G F Re x p r e s -
sion in 29 cases NSCLC with brain metastases. Nine
out of the 29 cases were studied regarding EGFR
expression in the lymph node metastases. Immunos-
taining was present in 84% (21/25) of the primary
tumors, in 56% (5/9) of the lymph nodes metastases,
and in 59% (17/29) of the brain metastases. However,
comparisons of paired samples from primary tumors
and corresponding metastases were not made. There
are conflicting results regarding the stability of EGFR
protein expression between paired samples of NSCLC
primary tumors and the corresponding metastases, and
our research add to the body of data on the subject.
Conclusions
T h eE G F Ri sc o m m o n l ye x p r e s s e di nN S C L C ,i t s
expression in the primary tumor and the corresponding
lymph node metastasis is discordant in about 10% of the
patients. When overexpression is considered, the discor-
dance is observed in about 20% of the cases. However,
concerning EGFR overexpression in the primary tumors,
similar expression in the metastases could be predicted
with a reasonably high probability, which is encouraging
for testing of EGFR targeted nuclide radiotherapy.
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